Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma.
作者信息
Kim Do Young
机构信息
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2023 Apr;29(2):335-338. doi: 10.3350/cmh.2023.0107. Epub 2023 Mar 20.
Abstract
摘要
相似文献
1
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma.迈向用户友好型和基于证据的肝细胞癌实践指南
Clin Mol Hepatol. 2023 Apr;29(2):335-338. doi: 10.3350/cmh.2023.0107. Epub 2023 Mar 20.
2
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
3
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
Eur J Cancer. 2012 Mar;48(5):599-641. doi: 10.1016/j.ejca.2011.12.021.
4
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
5
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?为缩小韩国肝细胞癌指南与实际临床实践之间的差异，应采取哪些措施？
Clin Mol Hepatol. 2023 Apr;29(2):332-334. doi: 10.3350/cmh.2023.0080. Epub 2023 Mar 16.
6
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].《中国原发性肝癌诊疗规范（2019年版）》
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004.
7
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.2014年韩国肝脏研究学会-国立癌症中心肝细胞癌管理韩国实践指南
Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.
8
Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap.台湾肝细胞癌的临床实践指南与实际临床应用：弥合差距
Clin Mol Hepatol. 2023 Apr;29(2):349-351. doi: 10.3350/cmh.2023.0082. Epub 2023 Mar 20.
9
Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?肝细胞癌降期后患者是否符合肝移植条件？
Liver Transpl. 2011 Oct;17 Suppl 2:S109-16. doi: 10.1002/lt.22335.
10
[Diagnostic imaging and therapy of hepatocellular carcinoma].[肝细胞癌的诊断成像与治疗]
Dtsch Med Wochenschr. 1997 Dec 12;122(50):1573-5.
本文引用的文献
1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
2
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.肝细胞癌的临床实践指南与实际临床实践：韩国视角。
Clin Mol Hepatol. 2023 Apr;29(2):197-205. doi: 10.3350/cmh.2022.0404. Epub 2023 Jan 5.
3
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
4
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.一线阿替利珠单抗联合贝伐单抗治疗进展后使用多激酶抑制剂治疗晚期肝细胞癌患者的临床结局：一项多国多中心回顾性研究
Liver Cancer. 2021 Apr;10(2):107-114. doi: 10.1159/000512781. Epub 2021 Mar 3.
5
Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool?非对比 MRI 用于肝细胞癌检测：系统评价和荟萃分析 - 一种潜在的监测工具？
Clin Gastroenterol Hepatol. 2022 Jan;20(1):44-56.e2. doi: 10.1016/j.cgh.2021.02.036. Epub 2021 Mar 2.
6
A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development.在肝癌发生高风险人群中，双年度两阶段低剂量肝脏CT与超声用于肝癌监测的比较
Liver Cancer. 2020 Sep;9(5):503-517. doi: 10.1159/000506834. Epub 2020 Aug 6.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey.肝切除术治疗多发性肝细胞癌：一项日本全国性调查。
Ann Surg. 2020 Jul;272(1):145-154. doi: 10.1097/SLA.0000000000003192.
9
Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.非对比磁共振成像与超声检查用于肝细胞癌监测的比较（MIRACLE-HCC）：一项前瞻性随机试验的研究方案。
BMC Cancer. 2018 Sep 24;18(1):915. doi: 10.1186/s12885-018-4827-2.
10
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.SIRveNIB：索拉非尼对比选择性内放射治疗在亚太地区肝细胞癌患者中的应用。
J Clin Oncol. 2018 Jul 1;36(19):1913-1921. doi: 10.1200/JCO.2017.76.0892. Epub 2018 Mar 2.
Zotero 插件